慢性乙型肝炎患者T淋巴细胞亚群与自然杀伤细胞活性分析

目的 分析慢性乙型肝炎患者外周血T淋巴细胞亚群与自然杀伤细胞(NK)的活性变化.方法 应用流式细胞技术分别检测35名健康入(A组)、31例乙型肝炎病毒携带(B组)、32例慢性乙型肝炎患者(C组)、30例急性乙型肝炎患者(D组),外周血T淋巴细胞CD4+、CD8+以及NK细胞,并分析各组间免疫细胞表达差异性.结果 C、D组CD4+ T淋巴细胞平均值为(32.45±10.45)％、(29.54±11.55)％较A、B组的(38.05±10.15)％、(37.17±11.22)％,明显降低,而CD8+ T淋巴细胞平均值为(36.15±11.56)％、(38.45±10.35)％,较A组的(30.14±11.25)(％),明显升高(P＜0.01); NK细胞则表现为C、D组平均值为(15.23±6.38)％、(12.07±5.95)％,较A、B组的(22.05±7.15)％、(20.32±7.67)％,明显降低(P＜0.05),以D组降低最为明显,A、B组差异无统计学意义.结论 慢性乙型肝炎和急性乙型肝炎患者外周血CD4+T淋巴细胞、NK细胞百分比降低,CD8+ T淋巴细胞升高；通过T淋巴细胞和NK细胞百分比检测可监测慢性乙型肝炎患者的免疫状态,为临床治疗时机的选择提供免疫学依据.

Investigation of T lymphocyte subsets and activity of natural killer cells in patients with chronic hepatitis B

OBJECTIVE To investigate the counts of natural killer(NK) cells and peripheral blood T lymphocyte subsets in patients with chronic hepatitis B.METHODS The CD4+T cells,CD8+ T cells,and NK cells in penripheral blood of 35 health persons(group A),32 patients with hepatitis B virus(group B),32 patients with chronic hepatitis B(group C) and 30 patients with acute hepatitis B(group D) were detected by using flow cytometry.RESULTS CD4+ T lymphocytes and NK cells of group C(32.45±10.45)%and group D(29.54±11.55)% were decreased significantly as compared with group A(38.05±10.15)% and group B(37.17±11.22)%,while CD8+ T lymphocytes of group C(36.15±11.56)% and group D(38.45±10.35)% was significantly increased as compared with group A(30.14±11.25)(P<0.01);the NK cells of group C(15.23±6.38)% and group D(12.07±5.95)% were significantly decreased as compared with the group A(22.05±7.15)% and group B(20.32±7.67)%,(P<0.05),group D decreased most significantly,the difference between group A and group B was not statistically significant.CONCLUSION The percentage of CD4+ T lymphocyte cells and NK cells in the peripheral blood of the patients with chronic or acute hepatitis B is decreased,while the percentage of CD8+ T lymphocyte cells is increased;through the detection of the percentage of T lymphocyte and NK cell we can monitor the immune status of the patients with chronic hepatitis B and get the reference of immunology for the clinical treatment.